Forsta AP Fonden Has $15.35 Million Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Forsta AP Fonden grew its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 7.8% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 60,700 shares of the medical research company’s stock after purchasing an additional 4,400 shares during the period. Forsta AP Fonden’s holdings in IQVIA were worth $15,350,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Los Angeles Capital Management LLC lifted its holdings in shares of IQVIA by 17.5% during the 4th quarter. Los Angeles Capital Management LLC now owns 118,616 shares of the medical research company’s stock worth $27,445,000 after acquiring an additional 17,677 shares during the period. Jennison Associates LLC lifted its stake in IQVIA by 7.3% in the 1st quarter. Jennison Associates LLC now owns 140,914 shares of the medical research company’s stock valued at $35,636,000 after purchasing an additional 9,578 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in IQVIA by 4.0% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,418,392 shares of the medical research company’s stock valued at $532,070,000 after purchasing an additional 93,194 shares during the last quarter. Cadian Capital Management LP bought a new position in IQVIA in the 4th quarter valued at approximately $70,108,000. Finally, Nomura Holdings Inc. bought a new position in IQVIA in the 4th quarter valued at approximately $857,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analyst Ratings Changes

IQV has been the subject of several recent research reports. StockNews.com cut shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Sunday, July 7th. Robert W. Baird dropped their price objective on shares of IQVIA from $241.00 to $235.00 and set a “neutral” rating on the stock in a research note on Wednesday. Truist Financial dropped their price objective on shares of IQVIA from $297.00 to $292.00 and set a “buy” rating on the stock in a research note on Friday, May 3rd. The Goldman Sachs Group started coverage on shares of IQVIA in a research note on Thursday, June 6th. They issued a “buy” rating and a $270.00 price objective on the stock. Finally, Barclays dropped their price target on shares of IQVIA from $275.00 to $255.00 and set an “overweight” rating on the stock in a research report on Friday, June 28th. Four analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat, IQVIA presently has a consensus rating of “Moderate Buy” and a consensus target price of $255.73.

IQVIA Stock Performance

IQV stock traded up $4.73 during mid-day trading on Friday, hitting $224.17. The company had a trading volume of 1,362,151 shares, compared to its average volume of 1,254,143. The firm has a market cap of $40.84 billion, a PE ratio of 30.62, a price-to-earnings-growth ratio of 2.04 and a beta of 1.49. The company has a debt-to-equity ratio of 2.02, a quick ratio of 0.88 and a current ratio of 0.88. IQVIA Holdings Inc. has a 12 month low of $167.42 and a 12 month high of $261.73. The stock’s fifty day moving average price is $219.72 and its two-hundred day moving average price is $228.98.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Thursday, May 2nd. The medical research company reported $2.30 EPS for the quarter, topping the consensus estimate of $2.19 by $0.11. The business had revenue of $3.74 billion for the quarter, compared to analyst estimates of $3.69 billion. IQVIA had a net margin of 9.01% and a return on equity of 29.17%. On average, analysts forecast that IQVIA Holdings Inc. will post 10.11 earnings per share for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.